Jaguar Health Provides Company Updates and Reports 2022 First Quarter Financials Mytesi net revenue of $2.6 million increased approximately 24% over the fourth quarter of 2021 and increased approximately 112% over Mytesi

Jaguar Health Provides Company Updates and Reports

2022 First Quarter Financials

Mytesi net revenue of $2.6 million

increased approximately 24% over the fourth quarter of 2021 and increased approximately 112% over Mytesi net revenue in the first quarter

Phase 3 clinical trial of crofelemer for prophylaxis of cancer therapy-related diarrhea (CTD) adding international sites, targeting completion

of enrollment 1H 2023

Targeted completion in 2022 & 2023 of investigator-initiated proof-of-concept studies of crofelemer for short bowel syndrome and

congenital diarrheal disorders, supporting the potential for expanded patient access through programs in Europe in 2023

Ongoing launch of Canalevia -CA1, which is now commercially available for treatment of chemotherapy-induced diarrhea

REMINDER: Jaguar to host investor

webcast Tuesday, May 10th at 8:30 a.m. Eastern regarding first quarter 2022 financials and company updates; Click here

to register for webcast

SAN FRANCISCO, CA / May 10, 2022 / Jaguar Health, Inc.

(NASDAQ: JAGX) ("Jaguar" or the "Company") today provided company updates and reported consolidated first quarter

2022 financial results.

Mytesi net revenue was approximately $2.6 million in the first quarter

of 2022, representing an increase of approximately 24% over Mytesi net revenue in the fourth quarter of 2021, which totaled approximately

$2.1 million, and an increase of approximately 112% over Mytesi net revenue in the first quarter of 2021, which totaled approximately

"These increases in Mytesi revenue largely represent the important

and continuing realization of the benefits - from both a financial perspective and the standpoint of improved patient access -

from the shift Jaguar completed this past January to distributing Mytesi through a closed network of specialty pharmacies (rather than

to wholesalers that resell the product to retail pharmacies). I am also pleased to announce that Canalevia-CA1 (crofelemer), our prescription

product for chemotherapy-induced diarrhea (CID) in dogs, is now commercially available," said Lisa Conte, Jaguar's president and

CEO. "Regarding future commercial opportunities, Jaguar is focused on two important crofelemer pipeline development activities

in the next 12-15 months that are expected to be value-creating: the completion of enrollment for our Phase 3 pivotal OnTarget

trial of our core follow-on indication for crofelemer's novel mechanism of action, prophylaxis of cancer therapy-related diarrhea

(CTD) in humans; and the completion in 2022 and 2023 of investigator-initiated proof-of-concept studies of crofelemer for short bowel

syndrome (SBS) and congenital diarrheal disorders (CDD), supporting the potential for expanded patient access through programs in Europe

in 2023 for these devastating and catastrophic diseases and health situations for these patients, who are often on parenteral nutrition

for as long as 20 hours a day, seven days a week."

2022 MILESTONES, UPDATES & ACCOMPLISHMENTS:

"We look forward to 2022 continuing to be an exciting year, with

continued development initiatives for crofelemer - our pipeline within a product'; continuing efforts to forge license

and business development relationships, such as the recently completed license and distribution deal with Quadri Pharma for the MENA region;

our ongoing Canalevia-CA1 launch, and potential expansion of Canalevia conditional approval to exercise-induced diarrhea (EID) in dogs;

and continued growth in sales of Mytesi, with the successful completion of the shift to our specialty pharmacies distribution and continued

educational and promotional activities in 2022, including the recent launch of our telehealth initiative. Most importantly, we are pleased

with the realization of our mission of providing relief with a novel, plant-based, first-in-class mechanism of action to patients in need

- including patients for whom no alternative therapeutic options exist," Conte said.

2022 FIRST QUARTER COMPANY FINANCIAL RESULTS:

Mytesi net revenue was approximately $2.6 million in the first quarter

of 2022, representing an increase of approximately 24% over Mytesi net revenue in the fourth quarter of 2021, which totaled approximately

$2.1 million, and an increase of approximately 112% over Mytesi net revenue in the first quarter of 2021, which totaled approximately

"Mytesi total prescription volume, the metric we believe to be

the best indicator of patient demand, increased 14.6% in the first quarter of 2022 over the fourth quarter of 2021," said Ian Wendt,

Jaguar's Chief Commercial Officer. "As previously announced, the transition to a closed network of specialty pharmacies has resulted

in a meaningful reduction in Mytesi distribution costs as well as a higher average net price and assists in the preparation of the Company's

U.S. commercial distribution network for potential future indication expansion of crofelemer to other populations of patients with complex

medical needs, such as CTD and SBS. This transition has also allowed us to begin utilizing sales and prescription data directly provided

by our network of specialty pharmacies to more accurately track prescription volume, rather than relying on a third-party provider of

estimated data for this important performance metric."

The Company believes the availability of Mytesi through specialty pharmacies

represents a significant benefit to patients, as such pharmacies focus on complex and chronic conditions and offer a higher level of support

for prior authorizations, appeals, adherence counseling, and home delivery options.

Note Regarding Use of Non-GAAP Measures

The Company supplements its condensed consolidated financial

statements presented on a GAAP basis by providing gross sales, non-GAAP EBITDA, and non-GAAP recurring EBITDA, which are considered

non-GAAP under applicable SEC rules. Jaguar believes that the disclosure items of these non-GAAP measures provide investors with

additional information that reflects the basis upon which Company management assesses and operates the business. These non-GAAP

financial measures are not in accordance with GAAP and should not be viewed in isolation or as substitutes for GAAP net sales and

GAAP net loss and are not substitutes for, or superior to, measures of financial performance in conformity with GAAP.

Gross sales percentages issued by the Company are based on gross sales

figures that represent Mytesi orders placed by select Specialty Pharmacies with Jaguar's third-party logistics warehouse, less allowances

for rebates and discounts, which generate the cash flows for Napo Pharmaceuticals, Inc. ("Napo"), Jaguar's wholly owned

subsidiary. Gross sales are used internally by management as an indicator of and to monitor operating performance, including sales performance

of Mytesi, salesperson performance, and product growth or declines. Gross sales are not a measure that is recognized under accounting

principles generally accepted in the United States of America ("GAAP") and should not be considered as an alternative to net

sales, which is determined in accordance with GAAP, and should not be used alone as an indicator of operating performance in place of

net sales. Additionally, gross sales may not be comparable to similarly titled measures used by other companies, as gross sales have been

defined by the Company's internal reporting practices. In addition, gross sales may not be realized in the form of cash receipts

as promotional payments and allowances may be deducted from payments received from certain customers. Mytesi gross sales are reduced by

specialty pharmacy discounts, Medicare rebates, Medicaid rebates, 340B discounts, ADAP rebates, VA rebates, copay program costs, prompt

pay discounts, and returns based on historical trends to determine net sales.

The Company defines non-GAAP EBITDA as net loss before interest expense

and other expense, depreciation of property and equipment, amortization of intangible assets, share-based compensation expense and provision

for or benefit from income taxes. The Company defines non-GAAP Recurring EBITDA as non-GAAP EBITDA adjusted for certain non-recurring

revenues and expenses. Company management believes that non-GAAP EBITDA and non-GAAP Recurring EBITDA are meaningful indicators of Jaguar's

performance and provide useful information to investors regarding the Company's results of operations and financial condition.

Participation Instructions for Webcast

When: Tuesday, May 10, 2022, at 8:30 AM Eastern

Participant Registration & Access Link: Click

Replay Instructions for Webcast

Replay of the webcast on the investor relations

section of Jaguar's website: (click here)

About Jaguar Health, Jaguar Animal Health, Napo Pharmaceuticals,

Jaguar Health, Inc. is a commercial stage pharmaceuticals company

focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress,

including chronic, debilitating diarrhea. Jaguar Animal Health is a tradename of Jaguar Health. Jaguar Health's wholly owned subsidiary,

Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human pharmaceuticals from plants harvested

responsibly from rainforest areas. Our crofelemer drug product candidate is the subject of the OnTarget study, an ongoing pivotal

Phase 3 clinical trial for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy. Jaguar Health is the majority

shareholder of Napo Therapeutics S.p.A. (f/k/a Napo EU S.p.A.), an Italian corporation established by Jaguar Health in Milan, Italy in

2021 that focuses on expanding crofelemer access in Europe.

For more information about Jaguar Health, please visit https://jaguar.health.

For more information about Napo Pharmaceuticals, visit www.napopharma.com.

Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic

relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi is not indicated for the treatment